A 65-year-old woman presented with a 4-year history of progressive refractory diffuse pruritus. She had been diagnosed 4 months earlier with cutaneous T-cell lymphoma (CTCL) stage I (mycosis fungoides). After being treated unsuccessfully with PUVA for 31 sessions, she was eventually diagnosed with CTCL stage IVA 2 (S ezary syndrome) on the basis of severe worsening pruritus, erythroderma, palmoplantar keratoderma with skin ulcerations causing cellulitis (Fig. 1A) , left eye ectropion, lymphanedopathy, positive skin biopsy and left inguinal lymph node biopsy, raised lactate dehydrogenase, S ezary cells over 1000/lL with positive clonality, CD4/CD8 ratio: 12.5, and CT chest, abdomen and pelvis showing inguinal and axillary lymphadenopathy with no visceral involvement. With bexarotene, interferon-alfa, and extracorporeal photopheresis, her keratoderma stabilized (Fig. 1B) , and after 2 months of treatment with keratolytics (6% salicylic acid in 70% propylene glycol and clobetasol), it largely cleared. S ezary syndrome is CTCL stage IV and its incidence is 1 in 10,000,000 with predicted median survival between 2 and 4 years [1, 2] . Its skin changes are characteristic and clinicians should be alarmed to severe pruritus with keratoderma as to exclude lymphoma. Despite the possibility to use first-line agents as treatment, allogenic stem cell transplantation is considered the only curative approach.
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